{"entity":{"id":"jason-luke","kind":"person","name":"Jason J. Luke","aka":[],"tldr":"Led KEYNOTE-716, which extended adjuvant pembrolizumab to high-risk stage II melanoma.","summary":"Jason Luke was principal investigator of KEYNOTE-716, which showed adjuvant pembrolizumab reduces recurrence and distant metastasis in resected stage IIB and IIC melanoma, the first adjuvant immunotherapy approval in stage II disease. He runs one of the largest early-phase immunotherapy programmes in the United States and studies mechanisms of primary resistance to checkpoint blockade. He is active in SITC leadership.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Luke%20JJ%5BAuthor%5D%20melanoma%20pembrolizumab"}],"tags":["melanoma","adjuvant","early-phase"],"related":[],"cancers":["melanoma"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":["pd1"],"drugs":["pembrolizumab"],"companies":[],"institutions":["upmc-hillman","sitc"],"pathways":[],"terms":[],"trials":["keynote-716"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nature-reviews-clinical-oncology"],"dependsOn":[],"notes":[],"role":"Director, Cancer Immunotherapeutics Center, UPMC Hillman Cancer Center","institutionId":"upmc-hillman","specialisms":["Melanoma","Adjuvant immunotherapy","Early-phase immunotherapy","Immune resistance"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Luke%20JJ%5BAuthor%5D%20melanoma%20pembrolizumab"}],"papers":[{"title":"Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716)","journal":"Lancet","year":2022,"doi":"10.1016/S0140-6736(22)00562-1"},{"title":"Targeted agents and immunotherapies: optimizing outcomes in melanoma","journal":"Nature Reviews Clinical Oncology","year":2017,"doi":"10.1038/nrclinonc.2017.43"}]},"route":"/people/jason-luke/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"stage-ii-melanoma","kind":"cancer","name":"Stage IIB and IIC melanoma","route":"/cancers/stage-ii-melanoma/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"target":[{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"institution":[{"id":"sitc","kind":"institution","name":"Society for Immunotherapy of Cancer","route":"/institutions/sitc/"},{"id":"upmc-hillman","kind":"institution","name":"UPMC Hillman Cancer Center","route":"/institutions/upmc-hillman/"}],"trial":[{"id":"keynote-716","kind":"trial","name":"KEYNOTE-716","route":"/trials/keynote-716/"}],"journal":[{"id":"nature-reviews-clinical-oncology","kind":"journal","name":"Nature Reviews Clinical Oncology","route":"/journals/nature-reviews-clinical-oncology/"}]}}